第四季度营收为6.78亿美元，高于市场预期的6.251亿美元，尽管同比下滑30%，但美国市场新冠疫苗销 售表现稳健，缓解了投资者对收入持续萎缩的担忧。公司同时重申2026年营收增长目标为10%，传递出 业务企稳信号。 财务状况 2025年全年运营支出预期下调至50亿-52亿美元，较此前指引缩减2亿美元；年末现金储备预计达81亿美 元，高于此前65亿-70亿美元的预测，增强了财务韧性。第四季度每股亏损2.11美元，较去年同期的2.91 美元收窄，反映亏损面收缩。 经济观察网莫德纳(MRNA.O)于2026年2月13日发布2025年第四季度及全年财报后，股价单日大幅上涨 7.58%，收盘报43.15美元，创下年内新高。当日成交额达5.14亿美元，量比1.61，换手率3.05%，显著高 于近期平均水平。 股价异动原因 当日纳斯达克指数上涨0.42%，生物技术板块涨幅1.85%，行业情绪向好。 资金面与技术面 低估值(市盈率TTM为负)与高波动性吸引短期资金流入，单日振幅达8.90%，成交量为近月均值的1.6 倍。 未来发展 流感疫苗审批受挫(FDA以临床试验设计问题拒审mRNA-1010)可能延迟2028年盈亏平衡 ...

Core Insights - Moderna has announced a three-year strategic plan aiming for cash flow balance by 2028, focusing on oncology for new growth opportunities [1][5]. Financial Performance - In Q3 2024, Moderna reported revenue of $1 billion, a 45% decline compared to the same period in 2023, with a net loss of $200 million [3]. - The revenue from COVID-19 vaccines accounted for $971 million, while the recently approved RSV vaccine contributed only $2 million [3]. - The company has revised its 2025 revenue guidance down to $1.6 billion to $2 billion, reducing the upper limit by $200 million [3]. Stock Performance - Moderna's stock has plummeted over 95% from its peak of $484.47 in 2021, with a market cap dropping to approximately $9 billion by November 2025 [4]. Cost Management and Restructuring - To address losses, Moderna has reduced cash cost expectations for 2026 and 2027 to approximately $4.2 billion and $3.5 billion to $3.9 billion, respectively [5]. - The company has implemented a 10% workforce reduction and terminated four projects to streamline operations [5]. Vaccine Development Focus - Moderna plans to continue expanding its vaccine portfolio over the next three years, introducing three new seasonal vaccines: flu, COVID/flu combination, and norovirus vaccines [5]. - The company aims to leverage its experience from COVID-19 vaccine sales to promote other seasonal vaccines [9]. Oncology Pipeline - Long-term, Moderna is shifting its R&D focus towards oncology, with plans to invest more in this area post-2028 [10]. - The oncology pipeline includes personalized cancer vaccines, cancer antigen therapies, TCE therapies, and cell therapies [11]. Key Oncology Projects - mRNA-4157, a personalized mRNA cancer vaccine, has shown promising results in clinical trials, reducing the risk of recurrence and death in melanoma patients by 49% when combined with pembrolizumab [13]. - Moderna is preparing for the commercial production of mRNA-4157 at a dedicated facility in Massachusetts [13]. Conclusion - Moderna is navigating a challenging transition period, focusing on cost management and strategic realignment towards oncology to achieve cash flow balance and long-term growth [14].